Patients must not have any co-existing condition that would preclude full compliance with the study; no prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
Prior history of allergic reactions to docetaxel and/or to medications formulated with polysorbate 80
A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)
Polysorbate 20
History of severe hypersensitivity reaction (>= grade 3) to docetaxel, polysorbate 80 containing drugs, or any of the capsule components of enzalutamide, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene
History of allergic reactions or severe hypersensitivity reactions to drugs formulated with polysorbate 80 or antisense oligonucleotides
Prior therapy with cabazitaxel or to other drugs formulated with polysorbate 80
Patients with hypersensitivity to docetaxel or polysorbate 80 (Arm A only)
Any history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Please refer to Study Appendix O for a complete list of Polysorbate 80 containing drugs.
Known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80
polysorbate 20
Patients with a history of a hypersensitivity reaction to products containing polysorbate 80 (Tween 80)
Patients with a history of severe hypersensitivity reaction to Taxotere (docetaxel) or other drugs formulated with polysorbate 80
Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80
Patients with a history of severe hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80
Patients must not have a history of a grade 4 anaphylactic reaction to monoclonal antibody therapy or known hypersensitivity reactions to drugs formulated with polysorbate 90
History of severe hypersensitivity reaction to paclitaxel, docetaxel, or to other drugs formulated with polysorbate 80 or polyoxyethylated castor oil, or to vinflunine or other vinca alkaloids
History of severe hypersensitivity reaction (>= grade 3) to polysorbate 80 containing drugs
polysorbate 20
History of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80
History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or tryptophan containing substances. This would include L-tryptophan or 5-hydroxy-tryptophan supplements. Also patients with a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80 are excluded.
Patients with a history of severe hypersensitivity reaction to JEVTANA (cabazitaxel) or other drugs formulated with polysorbate 80
E 16. History of hypersensitivity to docetaxel, or polysorbate 80.
History of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80
Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80
History of hypersensitivity to polysorbate 80
Hypersensitivity to polysorbate 80
Patients with known prior severe hypersensitivity reactions to cabazitaxel or other agents containing polysorbate 80
The subject has a history of severe hypersensitivity reactions to drugs formulated with polysorbate 80;
History of severe hypersensitivity reaction to polysorbate 80
Part 2 only: Patients with a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 (for example, drugs formulated with polysorbate 80 include, but are not limited to: Aranesp, Eprex, Cordarone, some vaccines).
History of allergic reactions or severe hypersensitivity reactions to drugs formulated with polysorbate 80 or antisense oligonucleotides.
Has a known sensitivity to capecitabine, any of its components, or other drugs formulated with polysorbate 80
History of severe hypersensitivity reaction to drugs formulated with polysorbate 80
Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 are excluded from participation
History of hypersensitivity to docetaxel or polysorbate 80
Patient has prior hypersensitivity reaction or intolerance to docetaxel or other drugs formulated with polysorbate 80
Hypersensitivity to pembrolizumab or history of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
Patients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold)
Subject has received colony-stimulating growth factor(s) within 7 days prior to screening (or within 14 days if subject received polyethylene glycol formulations).
Patient does not have known allergy to polyethylene glycol hydrogel (spacer material)
History of severe allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to STA-9090 (eg. Polyethylene glycol [PEG] 300 and Polysorbate 80)
Patients must be off all colony- forming growth factor(s) for at least 1 week prior to enrollment (i.e., filgrastim, sargramostim or erythropoietin); 2 weeks must have elapsed if patients received polyethylene glycol (PEG) formulations
Patients must be off all colony-forming growth factor(s) for at least 1 week prior to enrollment (i.e. filgrastim, sargramostim); two weeks must have elapsed if patients received polyethylene glycol (PEG) formulations
Subjects with a known allergy to polyethylene glycol hydrogel (spacer material) or contraindication to spacer products (Duraseal or SpaceOAR)
Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors
Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long-acting (e.g. polyethylene glycol [PEG]-filgrastim)
History of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin); 14 days must have elapsed if patients received poly(ethylene glycol) (PEG) formulations
History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
History of severe allergic or hypersensitivity reactions to excipients (e.g., polyethylene glycol [PEG] 300 and polysorbate 80)
Patients who may have insufficient renal capacity for clearance of Progel® polyethylene glycol load
Known hypersensitivity to polyethylene glycol (PEG) 300
History of anaphylactic reaction attributed to any contrast agent or drugs containing polyethylene glycol (PEG).
History of anaphylactic reaction attributed to any contrast agent or drugs containing polyethylene glycol (PEG).
History of anaphylactic reaction attributed to any contrast agent or drugs containing polyethylene glycol (PEG).